Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, has announced its 300th successful regulatory submission using its technology-enabled services and software. The submissions include those to initiate clinical trials and marketing applications. Certara's team of drug development and submission specialists have supported global submissions to various regulatory authorities including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada. In addition to regulatory submission services, Certara offers a software portfolio that aids in submission development.